#vacances

DYRK1A,

related kinases

& human disease conference

Saint-Malo, France

November 22-26, 2022

General information

General presentation

All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.

DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.

The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.

Location

Palais du Grand Large, St Malo, Bretagne, France

www.pgl-congres.com

Scientific information

Organizers

Laurent MEIJER

Perha Pharmaceuthicals,

Roscoff, France

Masatoshi HAGIWARA

Department of Anatomy

& Developmental Biology,

Graduate School of Medicine,

Kyoto University, Kyoto, Japan

Peter P. DE DEYN

Department of Neurology,

General Hospital Middelheim and Institute Born-Bunge University of Antwerp,

Antwerpen, Belgium

Contact

dyrk-conference@perha-pharma.com

Mariona ARBONES, Barcelona, Spain

Control of neuron numbers by DYRK1A: lessons from mouse models

Walter BECKER, Aachen, Germany

DYRK1B – a cancer drug target?

Thierry BESSON, Rouen, France

Novel DYRKs/CLKs inhibitors

Mara DIERSSEN, Barcelona, Spain

Clinical trials with EGCG, PERSEUS trial

Peter DE DEYN, Antwerpen, Belgium

Down syndrome, Alzheimer’s disease & DYRK1A

Susana DE LA LUNA, Barcelona, Spain

DYRK1A & DNA damage

Masatoshi HAGIWARA, Kyoto, Japan

Development of inhibitors of CLK1 and DYRK1A, and their clinical applications

Yann HERAULT, Strasbourg, France

The role of DYRK1A dosage in Down syndrome deficits

Florian HEYD, Berlin, Germany

CLK in body temperature cycles

Nathalie JANEL, Paris, France

DYRK1A interactants, a link between Down's syndrome and Alzheimer’s disease

Stefan KNAPP, Frankfurt, Germany

Selective targeting of kinases regulation RNA splicing

Akiko KOBAYASHI, Kyoto, Japan

Neuroprotection through suppression of inflammation by DYRK inhibitors

Conrad KUNICK, Braunschweig, Germany

New DYRK1B inhibitors

Laurent MEIJER, Roscoff, France

Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical

applications

Lenka MUNOZ, Sydney, Australia

Phosphoproteomic screen in cells upon DYRK1A inhibition: identification of new DYRK1A down-stream

substrates

William M. OLD, Boulder & Aurora, USA

Revealing new functions of DYRK1A through interactome and substrate profiling

Sang Ki PARK, Pohang, Korea

Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal

morphogenesis

Lucas PELKMANS, Zurich, Switzerland

Kinase-controlled phase transition of membrane-less organelles in mitosis

Amélie PITON, Illkirch, France

DYRK1A, a gene frequently mutated in intellectual disability

Randall J. ROPER, Indianapolis, USA

DYRK1A and skeletal deficits associated with Down syndrome

Andrew F. STEWART, New York, USA

DYRK1A inhibitors for beta cell proliferation to treat diabetes

Invited speakers (tentative titles)

Program

The final program will be available in October 2022.

Abstract submission

Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), address, e-mail contact, abstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.

Submit abstract as an attached Word document, through the Conference e-mail address (dyrk-conference@perha-pharma.com), with your name as ‘subject’.

Abstract submission deadline: September 30, 2022.

Instructions for speakers

There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).

Call for authors

We plan to put together an open-access e-book collating articles on the conference topic. It will be published by Frontiers in Neurology (www.frontiersin.org). Contribution to this e-book will be open to everyone, whether attending or not to the conference. The plan is to have the final e-book ready by the opening of the conference. Please consider this opportunity. More information will be sent to the DYRKs/CLKs community in the coming months.

Travel

Travel grants for young researchers

The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers. Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/